Positive Media Coverage Somewhat Unlikely to Affect CareDx (CDNA) Stock Price

Share on StockTwits

Media coverage about CareDx (NASDAQ:CDNA) has trended positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a news impact score of 0.29 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.4252116269409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of CDNA opened at $8.47 on Friday. The company has a debt-to-equity ratio of -3.08, a quick ratio of 0.50 and a current ratio of 0.62. CareDx has a 12-month low of $0.76 and a 12-month high of $8.63.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Thursday, March 22nd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.05. The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $12.09 million. CareDx had a negative return on equity of 349.65% and a negative net margin of 114.79%. analysts forecast that CareDx will post -0.34 earnings per share for the current fiscal year.

A number of research firms have recently commented on CDNA. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of CareDx in a report on Wednesday, January 31st. Finally, ValuEngine downgraded CareDx from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. CareDx presently has an average rating of “Buy” and a consensus price target of $8.65.

In related news, insider Peter Maag sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 27th. The stock was sold at an average price of $7.87, for a total transaction of $118,050.00. Following the completion of the transaction, the insider now owns 272,037 shares in the company, valued at approximately $2,140,931.19. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://baseballnewssource.com/2018/04/06/caredx-cdna-earning-positive-news-coverage-report-finds/2030146.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.